Patent Application

App. No. 19/238,302

Abstract

Claims (109)

1 . A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject an antibody specific for IL-18BP, wherein the antibody interferes with the binding of IL-18 to IL-18BP and wherein the antibody comprises a heavy chain variable region (V H ) that comprises complementary determining region V H CDR1, V H CDR2, and V H CDR3 sequences and a light chain variable region (V L ) that comprises complementary determining region V L CDR1, V L CDR2, and V L CDR3 sequences, wherein:

a. the V H CDR1 sequence comprises the amino acid sequence of TQDYNAH (SEQ ID NO: 169); the V H CDR2 sequence comprises the amino acid sequence of YIHYSGQTYYNPSLKS (SEQ ID NO: 170); the V H CDR3 sequence comprises the amino acid sequence of NFGSIYVNYFDY (SEQ ID NO: 171); the V L CDR1 sequence comprises the amino acid sequence of SASSSVSYMY (SEQ ID NO: 172); the V L CDR2 sequence comprises the amino acid sequence of TSNLAS (SEQ ID NO: 173); and the V L CDR3 sequence comprises an amino acid sequence of QQYHSYPT (SEQ ID NO: 174) or an amino acid sequence comprising 1 to 2 amino acid substitutions thereof;

b. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 1-3, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 4-6, respectively;

c. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 7-9, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 10-12, respectively;

d. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 13-15, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 16-18, respectively;

e. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 19-21, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 22-24, respectively;

f. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 25-27, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 28-30, respectively;

g. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 31-33, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 34-36, respectively;

h. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 37-39, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 40-42, respectively;

i. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 43-45, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 46-48, respectively;

j. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 49-51, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 52-54, respectively;

k. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 55-57, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 58-60, respectively;

l. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 61-63, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 64-66, respectively;

m. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 67-69, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 70-72, respectively;

n. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 73-75, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 76-78, respectively;

o. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 79-81, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 82-84, respectively;

p. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 85-87, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 88-90, respectively;

q. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 91-93, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 94-96, respectively;

r. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 97-99, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 100-102, respectively;

s. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 103-105, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 106-108, respectively;

t. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 109-111, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 112-114, respectively;

u. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 115-117, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 118-120, respectively;

v. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 121-123, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 124-126, respectively;

w. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 127-129, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 130-132, respectively;

x. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 133-135, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 136-138, respectively;

y. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 139-141, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 142-144, respectively;

z. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 145-147, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 148-150, respectively;

aa. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 151-153, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 154-156, respectively;

bb. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 157-159, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 160-162, respectively;

cc. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 163-165, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 166-168, respectively;

dd. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 169-171, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 172-174, respectively;

ee. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 175-177, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 178-180, respectively;

ff. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 181-183, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 184-186, respectively;

gg. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 187-189, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 190-192, respectively;

hh. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 193-195, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 196-198, respectively;

ii. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 199-201, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 202-204, respectively;

jj. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 205-207, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 208-210, respectively;

kk. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 211-213, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 238-240, respectively;

ll. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 217-219, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 220-222, respectively;

mm. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 223-225, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 226-228, respectively;

nn. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 241-243, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 232-234, respectively;

oo. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 241-243, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 238-240, respectively;

pp. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 241-243, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 244-246, respectively;

qq. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 247-249, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 250-252, respectively;

rr. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 229-231, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 232-234, respectively; or

ss. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 235-237, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 238-240, respectively.

2 . The method of claim 1 (a) wherein the V L CDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 174, 228, 234, 240, and 252.

3 . The method of claim 1 wherein:

a. the V H comprises a sequence at least 70% identical to SEQ ID NO: 265, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 266;

b. the V H comprises a sequence at least 70% identical to SEQ ID NO: 267, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 268;

c. the V H comprises a sequence at least 70% identical to SEQ ID NO: 269, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 270;

d. the V H comprises a sequence at least 70% identical to SEQ ID NO: 271, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 272;

e. the V H comprises a sequence at least 70% identical to SEQ ID NO: 273, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 274;

f. the V H comprises a sequence at least 70% identical to SEQ ID NO: 275, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 276;

g. the V H comprises a sequence at least 70% identical to SEQ ID NO: 277, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 278;

h. the V H comprises a sequence at least 70% identical to SEQ ID NO: 279, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 280;

i. the V H comprises a sequence at least 70% identical to SEQ ID NO: 281, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 282;

j. the V H comprises a sequence at least 70% identical to SEQ ID NO: 283, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 284;

k. the V H comprises a sequence at least 70% identical to SEQ ID NO: 285, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 286;

l. the V H comprises a sequence at least 70% identical to SEQ ID NO: 287, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 288;

m. the V H comprises a sequence at least 70% identical to SEQ ID NO: 289, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 290;

n. the V H comprises a sequence at least 70% identical to SEQ ID NO: 291, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 292;

o. the V H comprises a sequence at least 70% identical to SEQ ID NO: 293, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 294;

p. the V H comprises a sequence at least 70% identical to SEQ ID NO: 295, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 296;

q. the V H comprises a sequence at least 70% identical to SEQ ID NO: 297, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 298;

r. the V H comprises a sequence at least 70% identical to SEQ ID NO: 299, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 300;

s. the V H comprises a sequence at least 70% identical to SEQ ID NO: 301, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 302;

t. the V H comprises a sequence at least 70% identical to SEQ ID NO: 303, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 304;

u. the V H comprises a sequence at least 70% identical to SEQ ID NO: 305, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 306;

v. the V H comprises a sequence at least 70% identical to SEQ ID NO: 307, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 308;

w. the V H comprises a sequence at least 70% identical to SEQ ID NO: 309, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 310;

x. the V H comprises a sequence at least 70% identical to SEQ ID NO: 311, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 312;

y. the V H comprises a sequence at least 70% identical to SEQ ID NO: 313, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 314;

z. the V H comprises a sequence at least 70% identical to SEQ ID NO: 315, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 316;

aa. the V H comprises a sequence at least 70% identical to SEQ ID NO: 317, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 318;

bb. the V H comprises a sequence at least 70% identical to SEQ ID NO: 319, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 320;

cc. the V H comprises a sequence at least 70% identical to SEQ ID NO: 321, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 322;

dd. the V H comprises a sequence at least 70% identical to SEQ ID NO: 323, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 324;

ee. the V H comprises a sequence at least 70% identical to SEQ ID NO: 325, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 326;

ff. the V H comprises a sequence at least 70% identical to SEQ ID NO: 327, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 328;

gg. the V H comprises a sequence at least 70% identical to SEQ ID NO: 329, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 330;

hh. the V H comprises a sequence at least 70% identical to SEQ ID NO: 331, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 332;

ii. the V H comprises a sequence at least 70% identical to SEQ ID NO: 333, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 334;

jj. the V H comprises a sequence at least 70% identical to SEQ ID NO: 335, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 336;

kk. the V H comprises a sequence at least 70% identical to SEQ ID NO: 337, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 338;

ll. the V H comprises a sequence at least 70% identical to SEQ ID NO: 339, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 340;

mm. the V H comprises a sequence at least 70% identical to SEQ ID NO: 345, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 342;

nn. the V H comprises a sequence at least 70% identical to SEQ ID NO: 345, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 344;

oo. the V H comprises a sequence at least 70% identical to SEQ ID NO: 345, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 346;

pp. the V H comprises a sequence at least 70% identical to SEQ ID NO: 347, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 348;

qq. the V H comprises a sequence at least 70% identical to SEQ ID NO: 341, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 342; or

rr. the V H comprises a sequence at least 70% identical to SEQ ID NO: 343, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 344.

4 . The method of claim 1 , wherein the disease or condition is a cancer, tumor, proliferative disease or disorder, myelodysplastic syndrome (MDS), or an infectious disease.

5 . The method of claim 4 , wherein the cancer or tumor expresses or overexpresses IL-18BP and/or IL-18, or wherein the proliferative disease or disorder is associated with increased expression of IL-18BP and/or IL-18.

6 . The method of claim 4 , wherein the cancer is selected from one or more of bone cancer, prostate cancer, melanoma (e.g., metastatic melanoma), pancreatic cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, leukemia (e.g., lymphocytic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, relapsed acute myeloid leukemia, hairy cell leukemias, acute lymphoblastic leukemias), lymphoma (e.g., non-Hodgkin's lymphomas, Hodgkin's lymphoma), hepatoma (hepatocellular carcinoma), sarcoma, B-cell malignancy, breast cancer, ovarian cancer, colorectal cancer, glioma, glioblastoma multiforme, meningioma, pituitary adenoma, vestibular schwannoma, primary CNS lymphoma, primitive neuroectodermal tumor (medulloblastoma), kidney cancer (e.g., renal cell carcinoma), bladder cancer, urothelial cancer, uterine cancer, esophageal cancer, brain cancer, head and neck cancers, cervical cancer, testicular cancer, thyroid cancer, and stomach cancer.

7 . The method of claim 4 , wherein the proliferative disease or disorder is selected from the group consisting of a lymphoproliferative disorder, a myeloproliferative disorder, proliferative enteritis, proliferative diabetic retinopathy, and a proliferative kidney disease.

8 . The method of claim 4 , wherein the infectious disease is selected from the group consisting of viral, bacterial, fungal, and protozoal infections.

9 . The method of claim 1 , wherein the antibody is administered in combination with an immune checkpoint modulatory agent, wherein the immune checkpoint modulatory agent is an antagonist of a inhibitory immune checkpoint molecule or an agonist of a stimulatory immune checkpoint molecule.

10 . The method of claim 1 , wherein the antibody is administered in combination with at least one chemotherapeutic agent.

11 . The method of claim 10 , wherein the chemotherapuetic agent is selected from the group consisting of an alkylating agent, anti-metabolite, cytotoxic antibiotic, topoisomerase inhibitor (type 1 or type II), and an anti-microtubule agent.

12 . The method of claim 1 , wherein the antibody is administered in combination with IL-18.

13 . The method of claim 1 , wherein the antibody is adminstered intravenously or subcutaneously.

14 . The method of claim 1 , wherein the antibody is administered with a pharmaceutically acceptable carrier.

15 . The method of claim 1 , wherein the antibody comprises an IgA, IgD, IgE, IgG, or IgM Fc domain, or a hybrid and/or variant thereof.

16 . The method of claim 14 , wherein the IgG Fc domain is IgG1, IgG2, IgG3, or IgG4.

17 . The method of claim 14 , wherein the IgA Fc domain is IgA1 or IgA2.

18 . The method of claim 14 , wherein the Fc domain is a human Fc domain.

19 . The method of claim 1 , wherein the antibody comprises a variant IgG Fc domain with increased effector function in humans relative to a wild type IgG Fc domain.

20 . The method of claim 1 , wherein the antibody is a monoclonal antibody, humanized antibody or an scFv.

Assignments (8)